0001677077 false 0001677077 2023-08-16 2023-08-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

  

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

____________________________________________________________

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

___________________________________________________________________

 

Date of Report (Date of earliest event reported):  August 16, 2023

 

ALZAMEND NEURO, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40483   81-1822909
(State or other jurisdiction of
incorporation or organization)		   (Commission File Number)   (I.R.S. Employer Identification No.)

 

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326

(Address of principal executive offices) (Zip Code)

 

(844) 722-6333

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

   Name of each exchange on which registered
Common Stock, $0.0001 par value   ALZN   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

   
 

 

Item 8.01 Other Events

 

In accordance with Release No. 69279 issued by the Securities and Exchange Commission (“SEC”) on April 2, 2013 (the “Report”), which Report provides guidance to issuers regarding the use of social media to disclose material non-public information, Alzamend Neuro, Inc., a Delaware corporation (the “Company”) intends to use X (formerly known as Twitter) from time to time to communicate with the public about the Company and its business. The X account of the Company is https://x.com/AlzamendNeuro.

 

In addition, the Company intends to use LinkedIn from time to time to communicate with the public about the Company and its business. The Company’s LinkedIn page is https://www.linkedin.com/company/alzamend-neuro.

 

It is possible that the information that the Company posts on X and LinkedIn could be deemed to be material information. Therefore, in light of the SEC’s Report, we encourage investors, the media, and others interested in the Company to review the information that the Company’s post on X or LinkedIn in addition to the information that the Company discloses using its investors tab page on its website (https://www.alzamend.com), SEC filings, press releases, public conference calls and webcasts.

 

Item 9.01Financial Statements and Exhibits

 

(d)Exhibits:

 

Exhibit No.    Description
     
     
101   Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

 

 -2- 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ALZAMEND NEURO, INC.
   
   
Dated: August 16, 2023 /s/ Henry Nisser  
 

Henry Nisser

Executive Vice President and General Counsel

 

 

-3-

 

 

 

 

 

v3.23.2
Cover
Aug. 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 16, 2023
Entity File Number 001-40483
Entity Registrant Name ALZAMEND NEURO, INC.
Entity Central Index Key 0001677077
Entity Tax Identification Number 81-1822909
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3480 Peachtree Road NE
Entity Address, Address Line Two Second Floor
Entity Address, Address Line Three Suite 103
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30326
City Area Code (844)
Local Phone Number 722-6333
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol ALZN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Alzamend Neuro (NASDAQ:ALZN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Alzamend Neuro 차트를 더 보려면 여기를 클릭.
Alzamend Neuro (NASDAQ:ALZN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Alzamend Neuro 차트를 더 보려면 여기를 클릭.